
Marker Therapeutics Inc MRKR.OQ MRKR.O is expected to show a fall in quarterly revenue when it reports results on May 13 (estimated) for the period ending March 31 2025
The Houston Texas-based company is expected to report a 59.8% decrease in revenue to $500 thousand from $1.24 million a year ago, according to the mean estimate from 2 analysts, based on LSEG data.
LSEG's mean analyst estimate for Marker Therapeutics Inc is for a loss of 49 cents per share.
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts had risen by about 21.3% in the last three months.
Wall Street's median 12-month price target for Marker Therapeutics Inc is $10.25, above its last closing price of $1.28.
This summary was machine generated May 9 at 11:13 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)